41 results on '"Youdim, Moussa B. H."'
Search Results
2. Lewy bodies, iron, inflammation and neuromelanin: pathological aspects underlying Parkinson’s disease
3. Site-activated multi target iron chelators with acetylcholinesterase (AChE) and monoamine oxidase (MAO) inhibitory activities for Alzheimer’s disease therapy
4. Correction to: Lithium’s Gene Expression Profile, Relevance to Neuroprotection A cDNA Microarray Study
5. Treatment; Moussa B.H. Youdim
6. Creation of a gene expression classifier for predicting Parkinson’s disease rate of progression
7. Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases
8. A promising drug candidate for the treatment of glaucoma based on a P2Y6-receptor agonist
9. N-Methyl, N-propynyl-2-phenylethylamine (MPPE), a Selegiline Analog, Attenuates MPTP-induced Dopaminergic Toxicity with Guaranteed Behavioral Safety: Involvement of Inhibitions of Mitochondrial Oxidative Burdens and p53 Gene-elicited Pro-apoptotic Change
10. Beneficial Effects of Multitarget Iron Chelator on Central Nervous System and Gastrocnemius Muscle in SOD1G93A Transgenic ALS Mice
11. Additive Neuroprotective Effects of the Multifunctional Iron Chelator M30 with Enriched Diet in a Mouse Model of Amyotrophic Lateral Sclerosis
12. Lithium’s Gene Expression Profile, Relevance to Neuroprotection A cDNA Microarray Study
13. Effects of novel neuroprotective and neurorestorative multifunctional drugs on iron chelation and glucose metabolism
14. Multi-target, Neuroprotective and Neurorestorative M30 Improves Cognitive Impairment and Reduces Alzheimer's-Like Neuropathology and Age-Related Alterations in Mice
15. Chronic treatment with serotonin reuptake inhibitor antidepressant (SSRI) combined with an antipsychotic regulates GABA-A receptor in rat prefrontal cortex
16. Microarray expression profiling in 6-hydroxydopamine-induced dopaminergic neuronal cell death
17. Translocation and oligomerization of Bax is regulated independently by activation of p38 MAPK and caspase-2 during MN9D dopaminergic neurodegeneration
18. Site-Activated Chelators Derived from Anti-Parkinson Drug Rasagiline as a Potential Safer and More Effective Approach to the Treatment of Alzheimer’s Disease
19. Limited Potentiation of Blood Pressure in Response to Oral Tyramine by the Anti-Parkinson Brain Selective Multifunctional Monoamine Oxidase-AB Inhibitor, M30
20. Recent advances in amyotrophic lateral sclerosis research: perspectives for personalized clinical application
21. Restoration of Nigrostriatal Dopamine Neurons in Post-MPTP Treatment by the Novel Multifunctional Brain-Permeable Iron Chelator-Monoamine Oxidase Inhibitor Drug, M30
22. Molecular mechanisms underlying synergistic effects of SSRI–antipsychotic augmentation in treatment of negative symptoms in schizophrenia
23. Genomic and proteomic study to survey the mechanism of action of the anti-Parkinson’s disease drug, rasagiline compared with selegiline, in the rat midbrain
24. Glyceraldehyde-3-Phosphate Dehydrogenase–Monoamine Oxidase B-Mediated Cell Death-Induced by Ethanol is Prevented by Rasagiline and 1-R-Aminoindan
25. Comparative Neuroprotective Effects of Rasagiline and Aminoindan with Selegiline on Dexamethasone-Induced Brain Cell Apoptosis
26. The Novel Cholinesterase–Monoamine Oxidase Inhibitor and Antioxidant, Ladostigil, Confers Neuroprotection in Neuroblastoma Cells and Aged Rats
27. Biomarkers for evaluation of clinical efficacy of multipotential neuroprotective drugs for Alzheimer’s and Parkinson’s diseases
28. Multifunctional neuroprotective derivatives of rasagiline as anti-alzheimer’s disease drugs
29. Brain iron deficiency and excess; cognitive impairment and neurodegenration with involvement of striatum and hippocampus
30. Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil
31. Iron and α-synuclein in the substantia nigra of MPTP-treated mice: Effect of neuroprotective drugs R-apomorphine and green tea polyphenol (−)-epigallocatechin-3-gallate
32. Redox imbalance
33. Neuroprotective Strategies in Parkinson’s Disease: An Update on Progress
34. Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease
35. Green tea polyphenol (−)-epigallocatechin-3-gallate protects rat PC12 cells from apoptosis induced by serum withdrawal
36. Early and Late Gene Changes in MPTP Mice Model of Parkinson's Disease Employing cDNA Microarray
37. Early and late molecular events in neurodegeneration and neuroprotection in Parkinson’s disease MPTP model as assessed by cDNA microarray; the role of iron
38. Molecular Basis of Neuroprotective Activities of Rasagiline and the Anti-Alzheimer Drug TV3326 [lpar;N-Propargyl-(3R) Aminoindan-5-YL)-Ethyl Methyl Carbamate]
39. Strategies for the protection of dopaminergic neurons against neurotoxicity
40. Multifunctional drugs as neurotherapeutics
41. Preface
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.